Join us for the next FemTech Fridays (live) featuring Mitch Rosen, a leader with 25+ years of experience launching game-changing women’s health innovations around the world. From IUDs and hormone therapy to non-hormonal birth control and infection treatments, Mitch has helped bring critical solutions like Phexxi and SOLOSEC to market. A passionate advocate, he also serves on the board of Healthy Futures of Texas. Mitch is also neurodivergent, on the autism spectrum–something he considers a superpower in his professional role, enabling him to see connections and solutions in unique ways.
Tune in as we explore his journey, his vision for the future of FemTech, and how innovation can better serve women’s health!
Title: FemTech Fridays—Marketing the Taboo: How I Helped Bring Breakthroughs in Women’s Health to Market Speaker: Mitch Rosen
Time & Date: 10/17/25 from 12 PM – 12:30 PM
Livestream links: YouTube | LinkedIn
About the FemTech Program
For too long, women’s health has been overlooked in research and technology. The FemTech Program is changing that. The Program brings together brilliant minds from health care, tech, and business to create an ecosystem and solutions that work for women’s bodies and lives. Women make up half the population, yet they spend 25% of their lives in poor health. For much of medical history, their needs have been overlooked — women weren’t even required to be included in clinical trials until 1993. Despite making 80% of health care decisions for themselves and their families, conditions that affect billions of women receive minimal funding and limited technological innovation. FemTech is building a future where women’s health is prioritized through technology that works for women. The program is training the next generation of innovators to see and seize opportunities in women’s health, while fostering industry partnerships that connect researchers with companies to bring solutions to market faster. And at the heart of it all is a community of changemakers united by a shared commitment.
Read more . . .
